ABSI Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -7594.18% compared to Absci Corp.'s net margin of 49.9%. Absci Corp.'s return on equity of -59.51% beat CorMedix, Inc.'s return on equity of 95.25%.

Absci Corp. has a consensus price target of $8.26, signalling upside risk potential of 124.99%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 53.35%. Given that Absci Corp. has higher upside potential than CorMedix, Inc., analysts believe Absci Corp. is more attractive than CorMedix, Inc..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Absci Corp. quarterly revenues are $378K, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Absci Corp.'s net income of -$28.7M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Absci Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 6.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 166.33x versus 4.17x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech, Inc. has a net margin of -7594.18% compared to Absci Corp.'s net margin of 50.07%. Absci Corp.'s return on equity of -59.51% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Absci Corp. has a consensus price target of $8.26, signalling upside risk potential of 124.99%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 196.96%. Given that Fortress Biotech, Inc. has higher upside potential than Absci Corp., analysts believe Fortress Biotech, Inc. is more attractive than Absci Corp..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci Corp. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Absci Corp. quarterly revenues are $378K, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Absci Corp.'s net income of -$28.7M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Absci Corp.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 166.33x versus 1.70x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -7594.18% compared to Absci Corp.'s net margin of -1144.46%. Absci Corp.'s return on equity of -59.51% beat Ocugen, Inc.'s return on equity of -345.08%.

Absci Corp. has a consensus price target of $8.26, signalling upside risk potential of 124.99%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 508.11%. Given that Ocugen, Inc. has higher upside potential than Absci Corp., analysts believe Ocugen, Inc. is more attractive than Absci Corp..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci Corp. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Absci Corp. quarterly revenues are $378K, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Absci Corp.'s net income of -$28.7M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Absci Corp.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 166.33x versus 81.23x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -7594.18% compared to Absci Corp.'s net margin of -876.34%. Absci Corp.'s return on equity of -59.51% beat Verastem, Inc.'s return on equity of -1773.4%.

Absci Corp. has a consensus price target of $8.26, signalling upside risk potential of 124.99%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 102.53%. Given that Absci Corp. has higher upside potential than Verastem, Inc., analysts believe Absci Corp. is more attractive than Verastem, Inc..

Absci Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

Absci Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci Corp. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Absci Corp. quarterly revenues are $378K, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Absci Corp.'s net income of -$28.7M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Absci Corp.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci Corp. is 166.33x versus 36.92x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.